{"entity":{"id":"gi-innovation","kind":"company","name":"GI Innovation","aka":["GI Innovation, Inc."],"tldr":"GI Innovation is a South Korea-based biotechnology company that leads 3 cancer trials in OnCo, testing the bispecific fusion proteins GI-101, GI-102 and GI-108 in non-small-cell lung cancer, head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma and renal cell carcinoma.","summary":"GI Innovation is a South Korean biotechnology company developing bispecific fusion protein drugs on its GI-SMART platform for immuno-oncology and allergy. Its lead cancer candidates are GI-101 and GI-102 (CD80 and IL-2 variant fusion proteins) and GI-108 (anti-CD73 with an IL-2 variant), in phase 1/2 trials in Korea, the United States and Australia. On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in OnCo: NCT07172802 (phase 1/2, A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy...), NCT05824975 (phase 1/2, A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and...) and NCT04977453 (phase 1/2, GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.gi-innovation.com"},{"label":"ClinicalTrials.gov: trials led by GI Innovation","url":"https://clinicaltrials.gov/search?lead=GI%20Innovation%2C%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc","head-and-neck","pancreatic","rcc","sarcoma","ovarian","hcc","colorectal","melanoma","cervical","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["doxorubicin","paclitaxel","bevacizumab","eribulin","trastuzumab-deruxtecan","pembrolizumab","lenvatinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07172802","nct05824975","nct04977453"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Seoul","country":"KR","companyType":"biotech","website":"https://www.gi-innovation.com","ticker":"KOSDAQ:358570","stage":"public","investors":[],"funding":[]},"route":"/companies/gi-innovation/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"},{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"doxorubicin","kind":"drug","name":"Doxorubicin","route":"/drugs/doxorubicin/"},{"id":"eribulin","kind":"drug","name":"Eribulin","route":"/drugs/eribulin/"},{"id":"lenvatinib","kind":"drug","name":"Lenvatinib","route":"/drugs/lenvatinib/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/"}],"trial":[{"id":"nct07172802","kind":"trial","name":"A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors","route":"/trials/nct07172802/"},{"id":"nct05824975","kind":"trial","name":"A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizu","route":"/trials/nct05824975/"},{"id":"nct04977453","kind":"trial","name":"GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors","route":"/trials/nct04977453/"}]}}